Search
opicapone (ONGENTYS)
Indications:
- treatment of off episodes in Parkinson's disease patients treated with levodopa/carbidopa
Dosage:
- once daily
Tabs: 25 mg, 50 mg
Adverse effects:
- dyskinesia
- constipation
- increase in serum creatine kinase
- hypotension/syncope
- weight loss
Mechanism of action:
- selective catechol-O-methyltransferase inhibitor (COMT inhibitor)
General
pharmacologic agents for treatment of Parkinson's disease
enzyme inhibitor
Database Correlations
PUBCHEM cid=135565903
References
- CISION PR Newswire. April 27, 2020
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS
(opicapone) as an Add-On Treatment for Patients with Parkinson's
Disease Experiencing "Off" Episodes.
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-once-daily-ongentys-opicapone-as-an-add-on-treatment-for-patients-with-parkinsons-disease-experiencing-off-episodes-301047469.html